|
Israel Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Israel Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Israel.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Israeli pharmaceutical and healthcare industry.
Competitive intelligence, Israeli pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Israeli market.
The Israel Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Israel Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Israeli pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Israel to test other views – a key input for successful budgeting and strategic business planning in the Israeli pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Israeli Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Israel.
- Exploit The Latest Competitive Israeli Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Israel.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Israel Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Israel Pharmaceuticals And Healthcare Industry SWOT |
| Israel Political SWOT |
| Israel Economics SWOT |
| Israel Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings for Q209 |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Israel – Market Summary |
| Regulatory Regime |
| Intellectual Property |
| Shortcomings Of The IP Environment |
| Counterfeit Drugs |
| Table: Top 10 Countries By Counterfeit Pharmaceutical Seizures, 2006 |
| Pricing System |
| Reimbursement System |
| Funding For Reimbursement |
Chapter - Industry Trends |
| Epidemiology |
| Healthcare Sector |
| Healthcare Financing |
| Pharmaceutical Industry |
| Recent Pharmaceutical Industry Developments |
| Retail Pharmacy Sector |
| Research And Development Sector |
| Table: Israel's R&D Law – Conditions For OCS Funding |
| Biotechnology |
| International Research And Development Co-operation |
| Private Sector |
| Medical Device Industry |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Israel – Drug Market Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Israel – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Israel – Economic Activity, 2004-2013 |
| Prescription Market Forecast |
| Table: Israel – Prescription Market Indicators, 2003-2013 (ILSmn unless otherwise stated) |
| Patented Market Forecast |
| Patented Market Forecast |
| Table: Israel – Patented Drug Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Israel - Generics Market Indicators, 2003-2013 |
| OTC Market Forecast |
| Table: Israel – OTC Market Indicators, 2003-2013 (ILSmn unless otherwise stated) |
| Medical Device Market Forecast |
| Table: Israel – Medical Device Market Indicators, 2003-2013 (US$mn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: Israel – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Israel – Other Healthcare Indicators, 2003-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Israeli Pharmaceutical Manufacturers, 2006 |
Chapter - Company Profiles |
| Multinationals |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Merck & Co |
| Indigenous Manufacturer Profiles |
| Teva Pharmaceutical Industries |
| Taro |
| Perrigo (Agis Industries) |
| Dexcel |
| Trima |
| Rekah |
Chapter - Country Snapshot: Israel Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Israel Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s updated Business Environment Rankings for Q209, Israel slipped down from fourth position to sixth, out of 17 Middle East and African (MEA) markets surveyed. The country draws include high per capita drug market expenditure, ageing population and sophisticated demand for patented drugs among sections of the population, although a risky regulatory environment serves to limit Israel’s overall score. In fact, although Israel’s largest regulatory failing comes in terms of its intellectual property (IP) laws, Israel is in no rush to improve its IP environment, despite international pressure from its ally, the US, Consequently, despite its advanced status, Israel’s pharmaceutical market is unlikely to majorly improve its position in BMI’s regional matrix in the coming months.
In the meantime, strict pricing and reimbursement environment will result in a subdued growth of the Israeli drug expenditure in the coming five years. The value of the market, estimated at US$1.53bn in 2008, is forecast to increase at a compound annual growth rate (CAGR) of 3.75% in local currency terms through 2013, to reach the value of US$1.87bn at consumer prices. Population ageing and the increased number of drugs added to the government’s subsidised medicine basket will be the main drivers of this upward trend, although the threat of a possible price reduction of 35% continues to loom large. Additionally, as Israel’s GDP growth is expected to slow dramatically in 2009 – due to falling demand for Israeli exports, sluggish consumer spending and negative investor sentiment – the government is likely to increase its healthcare cost-containment focus. However, proposals such as the one to charge housewives and other non-salaried people for access to healthcare are certain to cause public discontent.
In other developments, local press reported in February 2009 that all sick funds were fined by the Ministry of Health for overspending their advertising budgets for 2007. Consequently, the healthcare funds – which effectively impose their own pharmaceutical prices on drugmakers, due to their considerable bargaining power – will receive much lower advertising budgets for 2009. While the minimum ‘basket’ of healthcare services is guaranteed by law, lower marketing revenues for the sick funds may translate into falling membership, which could increase their attempt to secure the lowest prices for pharmaceutical products as well as other medical services.
Difficulties in its home market are resulting in local drugmakers, led by stalwart Teva, to continue their expansion abroad. Following the December 2008 completion of its acquisition of US generics specialist Barr, Teva recently formed a partnership with Switzerland's Lonza to produce biosimilars. The deal signals the expanding drugmakers’ interest into entering the biopharmaceutical sector to increase revenues. Teva is clearly preparing for its own mini patent cliff in 2014, following the announcement that its US-based generics rival Mylan is planning to develop a generic version of its innovative multiple sclerosis (MS) branded generics blockbuster Copaxone (glatiramer).
|
Israel Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |